- In November 2021, ADVANZ PHARMA launched MYRELEZ (lanreotide) in Norway, the first generic version of lanreotide for treating acromegaly, grade 1, and certain grade 2 gastroenteropancreatic neuroendocrine tumors, as well as symptoms related to neuroendocrine tumors
- In September 2021, Amolyt Pharma and PeptiDream Inc. announced that Amolyt Pharma exercised its option to globally license a portfolio of growth hormone receptor antagonists (GHRA) for developing AZP-3813. This drug candidate is being explored as a potential acromegaly treatment in combination with somatostatin analogs for patients not responding to SSAs alone
